Integrin inhibitor cilengitide for the treatment of glioblastoma: A brief overview of current clinical results

Anticancer Research

Volumn 32, Issue 10, 2012, Pages 4213-4224

  Scaringi, Claudia ^a   Minniti, Giuseppe ^a   Caporello, Paola ^b   Enrici, Riccardo Maurizi ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Angiogenesis; Cilengitide; Integrins; Malignant glioma; Radiotherapy; Review

Indexed keywords

ALPHAVBETA5 INTEGRIN; CEDIRANIB; CETUXIMAB; CILENGITIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; FOCAL ADHESION KINASE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; MAMMALIAN TARGET OF RAPAMYCIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PROCARBAZINE; PROTEIN BAD; PROTEIN INHIBITOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAS PROTEIN; SOS PROTEIN; TEMOZOLOMIDE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; APOPTOSIS; ARTHRALGIA; BLOOD TOXICITY; BRAIN HEMORRHAGE; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL INTERACTION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHEMORADIOTHERAPY; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; EXTRACELLULAR MATRIX; FATIGUE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPONATREMIA; KIDNEY CARCINOMA; LIVER TOXICITY; LYMPHOCYTOPENIA; MELANOMA; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROPATHY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROMOTER REGION; RADIATION DOSE; RADIOSENSITIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHEMORADIOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DACARBAZINE; GLIOBLASTOMA; HUMANS; INTEGRINS; MICE; RATS; SIGNAL TRANSDUCTION; SNAKE VENOMS;

EID: 84867830537     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Deorah S, Lynch CF, Sibenaller ZA and Ryken TC: Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg Focus 20: E1, 2006.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005. (Pubitemid 40349501)
3. Minniti G, Amelio D, Amichetti M, Salvati M, Muni R, Bozzao A, Lanzetta G, Scarpino S, Arcella A and Enrici RM: Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide: Radiother Oncol 97: 377-381, 2010.
4. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, and Prados MD; North American Brain Tumor Consortium: A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol 12: 95-103, 2010.
5. Peereboom DM, Shepard DR, Ahluwalia MS, Brewer CJ, Agarwal N, Stevens GH, Suh JH, Toms SA, Vogelbaum MA, Weil RJ, Elson P and Barnett GH: Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 98: 93-99, 2010.
6. Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Fedoroff A, Sneed PK, Berger MS, McDermott MW, Parsa AT, Vandenberg S, James CD, Lamborn KR, Stokoe D and Haas-Kogan DA: Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 27: 579- 584, 2009.
7. Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton RF, Rowland KM Jr, Mischel P, Yong WH, Scheithauer BW, Schiff D, Giannini C and Buckner JC; North Central Cancer Treatment Group Study N0177: Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 26: 5603-5609, 2008.
8. Uhm JH, Ballman KV, Wu W, Giannini C, Krauss JC, Buckner JC, James CD, Scheithauer BW, Behrens RJ, Flynn PJ, Schaefer PL, Dakhill SR and Jaeckle KA: Phase II evaluation of gefitinib in patients with newly diagnosed grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. Int J Radiat Oncol Biol Phys 80: 347-353, 2011.
9. Prados MD, Yung WK, Wen PY, Junck L, Cloughesy T, Fink K, Chang S, Robins HI, Dancey J and Kuhn J: Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: A North American Brain Tumor Consortium study. Cancer Chemother Pharmacol 61: 1059-1067, 2008. (Pubitemid 351423127)
10. Franceschi E, Cavallo G, Lonardi S, Magrini E, Tosoni A, Grosso D, Scopece L, Blatt V, Urbini B, Pession A, Tallini G, Crinò L and Brandes AA: Gefitinib in patients with progressive high-grade gliomas: A multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 96: 1047-1051, 2007. (Pubitemid 46608313)
11. Reardon DA, Dresemann G, Taillibert S, Campone M, van den Bent M, Clement P, Blomquist E, Gordower L, Schultz H, Raizer J, Hau P, Easaw J, Gil M, Tonn J, Gijtenbeek A, Schlegel U, Bergstrom P, Green S, Weir A and Nikolova Z: Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer 101: 1995-2004, 2009.
12. Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PM, Frenay M, Rampling R, Stupp R, Kros JM, Heinrich MC, Gorlia T, Lacombe D and van den Bent MJ; European Organisation for Research and Treatment of Cancer Brain Tumor Group Study: Phase II study of imatinib in patients with recurrent gliomas of various histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 26: 4659-4665, 2008.
13. Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, McLendon RE, Provenzale JM, Rich JN, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS and Reardon DA: Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol 83: 53-60, 2007. (Pubitemid 46647165)
14. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C and Prados MD: Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12: 4899-4907, 2006. (Pubitemid 44338577)
15. Nabors LB, Supko JG, Rosenfeld M, Chamberlain M, Phuphanich S, Batchelor T, Desideri S, Ye X, Wright J, Gujar S and Grossman SA; New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium: Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. Neuro Oncol 13: 1324-1330, 2011.
16. Hainsworth JD, Ervin T, Friedman E, Priego V, Murphy PB, Clark BL, and Lamar RE: Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 116: 3663-3669, 2010.
17. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J and Prados MD; North American Brain Tumor Consortium and the National Cancer Institute: Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23: 357-361, 2005. (Pubitemid 40980358)
18. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M and Walsh DJ; North Central Cancer Treatment Group: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group study. J Clin Oncol 23: 5294-5304, 2005. (Pubitemid 46206983)
19. Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE 2nd, Marcello J, Kirkpatrick JP, Sampson JH, Bailey L, Threatt S, Friedman AH, Bigner DD and Friedman HS: The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 17: 4119-4124, 2011.
20. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, Kolevska T, Polikoff J, Fehrenbacher L, Elashoff R and Cloughesy T: Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29: 142-148, 2011.
21. Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M and Cloughesy T: Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: Interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 71: 1372-1380, 2008.
22. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY and Jain RK: Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28: 2817-2823, 2010.
23. Fields EC, Damek D, Gaspar LE, Liu AK, Kavanagh BD, Waziri A, Lillehei K and Chen C: Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 82: 51-57, 2012.
24. Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, Schiff D, Batchelor TT, Ligon KL, Young G, Muzikansky A, Weiss SE and Wen PY: Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 78: 85-90, 2010.
25. Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, Duda DG, Wen PY, Jain RK and Batchelor TT: Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol 103: 325-332, 2011.
26. Brandes AA, Stupp R, Hau P, Lacombe D, Gorlia T, Tosoni A, Mirimanoff RO, Kros JM and van den Bent MJ: EORTC study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur J Cancer 46: 348-354, 2010.
27. Reardon DA, Egorin MJ, Desjardins A, Vredenburgh JJ, Beumer JH, Lagattuta TF, Gururangan S, Herndon JE 2nd, Salvado AJ and Friedman HS: Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer 115: 2188-2198, 2009.
28. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M and Cloughesy T: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27: 4733-4740, 2009.
29. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS and Fine HA: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27: 740-745, 2009.
30. Takada Y, Ye X and Simon S: The integrins. Genome Biol 8: 215, 2007.
31. Huveneers S, Truong H and Danen HJ: Integrins: Signaling, disease, and therapy. Int J Radiat Biol 83: 743-751, 2007. (Pubitemid 350219110)
32. Desgrosellier JS and Cheresh DA: Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer 10: 9-22, 2010.
33. Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Böttcher S, Wynendaele W, Drevs J, Verweij J and van Oosterom AT: Phase I and pharmacokinetic study of continuous twiceweekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours. Eur J Cancer 39: 917-926, 2003. (Pubitemid 36428623)
34. Hariharan S, Gustafson D, Holden S, McConkey D, Davis D, Morrow M, Basche M, Gore L, Zang C, O'Bryant CL, Baron A, Gallemann D, Colevas D and Eckhardt SG: Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol 18: 1400-1407, 2007. (Pubitemid 47305015)
35. O'Donnell PH, Undevia SD, Stadler WM, Karrison TM, Nicholas MK, Janisch L and Ratain MJ: A phase I study of continuous infusion cilengitide in patients with solid tumors. Invest New Drugs 30: 604-610, 2012.
36. Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, Cloud GA, Zhang Y, Carson K, Wittemer SM, Colevas AD and Grossman SA: Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25: 1651-1657, 2007. (Pubitemid 46797943)
37. MacDonald TJ, Stewart CF, Kocak M, Goldman S, Ellenbogen RG, Phillips P, Lafond D, Poussaint TY, Kieran MW, Boyett JM and Kun LE: Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 26: 919-924, 2008. (Pubitemid 351398085)
38. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M and Nabors LB: Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26: 5610-5617, 2008.
39. Fink K, Mikkelsen T, Nabors LB, P. Ravin, S. R. Plotkin, D. Schiff, C. Hicking, M. Picard, and D. A. Reardon: Long-term effects of cilengitide, a novel integrin inhibitor, in recurrent glioblastoma: A randomized phase IIa study. J Clin Oncol 28: 15s, 2010 (suppl; abstr 2010).
40. Gilbert MR, Kuhn J, Lamborn KR, Lieberman F, Wen PY, Mehta M, Cloughesy T, Lassman AB, Deangelis LM, Chang S and Prados M: Cilengitide in patients with recurrent glioblastoma: The results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol 106: 147-153, 2012.
41. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M and Weller M: Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28: 2712-2718, 2010.
42. Nabors LB, Mikkelsen T, Batchelor T, Lesser G, Rosenfeld M, Ye X, Piantadosi S, Olson J, Brem S and Grossman S: NABTT 0306: A randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM). J Clin Oncol 27: 15s, 2009 (suppl; abstr 2001).
43. Alva A, Slovin S, Daignault S, Carducci M, Dipaola R, Pienta K, Agus D, Cooney K, Chen A, Smith DC and Hussain M: Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest New Drugs 30: 749-757, 2012.
44. Bradley DA, Daignault S, Ryan CJ, Dipaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross ME, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, Keller ET and Hussain M: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs 29: 1432-1440, 2011.
45. Friess H, Langrehr JM, Oettle H, Raedle J, Niedergethmann M, Dittrich C, Hossfeld DK, Stöger H, Neyns B, Herzog P, Piedbois P, Dobrowolski F, Scheithauer W, Hawkins R, Katz F, Balcke P, Vermorken J, van Belle S, Davidson N, Esteve AA, Castellano D, Kleeff J, Tempia-Caliera AA, Kovar A and Nippgen J: A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer 6: 285, 2006.
46. Vermorken JB, Guigay J, Mesia R, Trigo JM, Keilholz U, Kerber A, Bethe U, Picard M and Brummendorf TH: Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: Findings of the phase I part. Br J Cancer 104: 1691-1696, 2011.
47. Reardon DA, Nabors LB, Stupp R and Mikkelsen T: Cilengitide: An integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 17: 1225-1235, 2008.
48. Leblond P, Meignan S, Le Tinier F, Bethe U and Lansiaux A: The inhibitor of integrins Cilengitide: A new active drug in neuro-oncology. Bull Cancer 98: 1083-1090, 2011.
49. Aoudjit F and Vuori K: Integrin signaling inhibits paclitaxe-linduced apoptosis in breast cancer cells. Oncogene 20: 4995-5004, 2001. (Pubitemid 32769789)
50. Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF and Giachelli CM: NF-kB mediates αvβ3 integrin-induced endothelial cell survival. J Cell Biol 141: 1083-1093, 1998. (Pubitemid 28243974)
51. Courter DL, Lomas L, Scatena M and Giachelli CM: SRC kinase activity is required for integrin alphaVbeta3-mediated activation of nuclear factor-kB. J Biol Chem 280: 12145-12151, 2005.
52. Miyamoto S, Teramoto H, Gutkind JS and Yamada KM: Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: Roles of integrin aggregation and occupancy of receptors. J Cell Biol 135: 1633-1642, 1996. (Pubitemid 26427657)
53. Hynes RO: Integrins: Bidirectional, allosteric signaling machines. Cell 110: 673-687, 2002.
54. Stupack DG and Cheresh DA: A Bit-role for integrins in apoptosis. Nat Cell Biol 6: 388-389, 2004. (Pubitemid 38607497)
55. Adams JC and Engel J: Bioinformatic analysis of adhesion proteins. Methods Mol Biol 370: 147-172, 2007.
56. Avraamides CJ, Garmy-Susini B and Varner JA: Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 8: 604-617, 2008.
57. Gingras MC, Roussel E, Bruner JM, Branch CD and Moser RP: Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue. J Neuroimmunol 57: 143-153, 1995.
58. Gladson CL: Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors. J Neuropathol Exp Neurol 55: 1143-1149, 1996.
59. Hood JD and Cheresh DA: Role of integrins in cell invasion and migration. Nat Rev Cancer 2: 91-100, 2002. (Pubitemid 37328796)
60. Goodman SL, Hölzemann G, Sulyok GA and Kessler H: Nanomolar small molecule inhibitors for αvβ6, αvβ5, and αvβ3 integrins. J Med Chem 45: 1045-1051, 2002. (Pubitemid 34173914)
61. Belvisi L, Riccioni T, Marcellini M, Vesci L, Chiarucci I, Efrati D, Potenza D, Scolastico C, Manzoni L, Lombardo K, Stasi MA, Orlandi A, Ciucci A, Nico B, Ribatti D, Giannini G, Presta M, Carminati P and Pisano C: Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist. Mol Cancer Ther 4: 1670-1680, 2005.
62. Jonczyk A, Goodman S, Diefenbach B, Sutter A, Hölzemann G, Kessler H and Dechantsreiter M: Preparation of cyclic peptides as integrin inhibitors. DE 19534177; EP 0770622; JP 1997132593; US 6001961.
63. Dechantsreiter MA, Planker E, Mathä B, Lohof E, Hölzemann G, Jonczyk A, Goodman SL and Kessler H: N-Methylated cyclic RGD peptides as highly active and selective α(V)β(3) integrin antagonists. J Med Chem 42: 3033-3040, 1999. (Pubitemid 29384038)
64. Xiong JP, Stehle T, Zhang R, Joachimiak A, Frech M, Goodman SL and Arnaout MA: Crystal structure of the extracellular segment of integrin αVβ3 in complex with an Arg-Gly-Asp ligand. Science 296: 151-155, 2002. (Pubitemid 34280076)
65. Merck Serono http://www.merckserono.com
66. Mitjans F, Meyer T, Fittschen C, Goodman S, Jonczyk A, Marshall JF, Reyes G and Piulats J: In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int J Cancer 87: 716-723, 2000. (Pubitemid 30620415)
67. Nisato RE, Tille JC, Jonczyk A, Goodman SL and Pepper MS: αvβ3 and αvβ5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 6: 105-119, 2003. (Pubitemid 38173862)
68. Aguzzi MS, Giampietri C, De Marchis F, Padula F, Gaeta R, Ragone G, Capogrossi MC and Facchiano A: RGDS peptide induces caspase 8 and caspase 9 activation in human endothelial cells. Blood 103: 4180-4187, 2004. (Pubitemid 38685360)
69. Raguse JD, Gath HJ, Bier J, Riess H and Oettle H: Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral Oncol 40: 228-230, 2004. (Pubitemid 38030369)
70. Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R, Gröne HJ, Hallahan DE, Reisfeld RA, Debus J, Niethammer AG and Huber PE: Inhibition of α(v)β3integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 11: 6270-6279, 2005. (Pubitemid 41262958)
71. Lomonaco SL, Finniss S, Xiang C, Lee HK, Jiang W, Lemke N, Rempel SA, Mikkelsen T and Brodie C: Cilengitide induces autophagy-mediated cell death in glioma cells. Neuro Oncol 13: 857-865, 2011.
72. Skuli N, Monferran S, Delmas C, Favre G, Bonnet J, Toulas C and Cohen-Jonathan Moyal E: αvβ3/αvβ5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma. Cancer Res 69: 3308-3316, 2009.
73. Loges S, Butzal M, Otten J, Schweizer M, Fischer U, Bokemeyer C, Hossfeld DK, Schuch G and Fiedler W: Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro . Biochem Biophys Res Commun 357: 1016-1020, 2007. (Pubitemid 46695889)
74. Oliveira-Ferrer L, Hauschild J, Fiedler W, Bokemeyer C, Nippgen J, Celik I and Schuch G: Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/SRC/AKT pathway. J Exp Clin Cancer Res 27: 86, 2008.
75. Taga T, Suzuki A, Gonzalez-Gomez I, Gilles FH, Stins M, Shimada H, Barsky L, Weinberg KI and Laug WE: Alpha vintegrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 98: 690-697, 2002. (Pubitemid 34228889)
76. MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA and Laug WE: Preferential susceptibility of brain tumors to the antiangiogenic effects of an α(v) integrin antagonist. Neurosurgery 48: 151-157, 2001. (Pubitemid 32039837)
77. Yamada S, Bu XY, Khankaldyyan V, Gonzales-Gomez I, McComb JG and Laug WE: Effect of the angiogenesis inhibitor cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery 59: 1304-1312, 2006. (Pubitemid 44949775)
78. Buerkle MA, Pahernik SA, Sutter A, Jonczyk A, Messmer K and Dellian M: Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo. Br J Cancer 86: 788-795, 2002. (Pubitemid 34250824)
79. Albert JM, Cao C, Geng L, Leavitt L, Hallahan DE and Lu B: Integrin alpha v beta 3 antagonist cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small cell lung cancer models. Int J Radiat Oncol Biol Phys 65: 1536-1543, 2006. (Pubitemid 44425239)
80. Mikkelsen T, Brodie C, Finniss S, Berens ME, Rennert JL, Nelson K, Lemke N, Brown SL, Hahn D, Neuteboom B and Goodman SL: Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 124: 2719-2727, 2009.
81. Maurer GD, Tritschler I, Adams B, Tabatabai G, Wick W, Stupp R and Weller M: Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro . Neuro Oncol 11: 747-756, 2009.
82. Tentori L, Dorio AS, Muzi A, Lacal PM, Ruffini F, Navarra P and Graziani G: The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncol Rep 19: 1039-1043, 2008. (Pubitemid 351802678)
83. Jain RK: Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 19: 7-16, 2005.
84. ClinicalTrials.gov http://www.clinicaltrials.gov (last accessed March 2012).